MPLN News


epi-procolon.png

Letter to JAMA editor discussing colon cancer screening

Posted on November 04 2016 by J Seabrook

Dr Nicholas T. Potter Executive Vice President of Clinical Affairs at Molecular Pathology Laboratory Network Inc (MPLN), in a recent letter to the editor of Journal of the American Medical Association (JAMA) Oct 25 2016, clarified the performance…
Read more


AdobeStock_83774380.jpg

MPLN expands their oncology offering in CLL/SLL with IgVH Somatic Hypermutation by NGS

Posted on October 19 2016 by Jonathan Mulkey

CLL/SLL is the most common leukemia diagnosed among adults in Western countries and is associated with heterogeneous clinical outcomes.  IgVH somatic hypermutation (SHM) status is a primary component of the CLL International Prognostic Index…
Read more


New Legislation for Blood Based Testing for Colorectal Cancer Screening

Posted on October 10 2016 by J Seabrook

The 'Donald Payne Sr. Colorectal Cancer Detection Act of 2016" was introduced by Congressman Donald M. Payne, Jr. (D-NJ) and co-sponsored by Congressman Charles Dent (R-PA) and Congressman John Delaney (D-MD) in Washington D.C on Sept 29th.…
Read more


PD-L1_Hi_power_web.png

MPLN expands their oncology testing repertoire with PD-L1 and PD-1 immunohistochemistry assays

Posted on August 11 2016 by J Seabrook

Molecular Pathology Laboratory Network Inc. launches Ventana PD-L1 and PD-1 assays, expanding their oncology immunohistochemistry menu of tests for NSCLC and other tumor types. MPLN’s repertoire of integrated testing now includes the addition…
Read more


MPLN_CSP.jpg

MPLN partners with ArcherDX to offer ArcherĀ® NGS assays to global biopharma

Posted on July 19 2016 by J Seabrook

Boulder, COLORADO – ArcherDX, Inc., has announced that Molecular Pathology Laboratory Network, Inc. (MPLN) is now a Certified Service Provider of Archer® FusionPlex® NGS assays. MPLN will offer a custom sarcoma analysis service that…
Read more


1 2 3 4 5 6 7 8